Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
400 CHF | +388.82% | -.--% | -.--% |
10:24am | Merck: US approval for canine flu vaccine | CF |
25/06 | Merck's Animal Health Unit Says USDA Approves Dog Flu Vaccine | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 337B | - | ||
+55.24% | 815B | C+ | ||
+45.31% | 654B | B | ||
-6.72% | 354B | C+ | ||
+10.12% | 302B | C+ | ||
+17.75% | 247B | B+ | ||
+2.04% | 229B | A+ | ||
+12.91% | 219B | B- | ||
+9.80% | 171B | C+ | ||
-3.58% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MRK Stock
- MRK Stock
- Ratings Merck & Co., Inc.